Oral Anticoagulants … Is New Really Better?

Date: 
Wednesday, May 1, 2019 - 12:00pm to 1:00pm

Oral Anticoagulants … Is New Really Better?

Wednesday May 1st, 2019

12:00pm – 1:00PM (Central) – 1:00PM – 2:00PM (Eastern)

1.0  CE for both RNs (AANAC) and Administrators (NCERS/NAB)

NOTE:  Effective April 30, 2019 Missouri Administrators will now be NAB Approved

Warfarin, a Vitamin K Antagonist, was first discovered in 1939, it was introduced as an effective rodenticide.  It was FDA approved as Coumadin in 1954.

By adopting the International Normalized Ratio (INR) method of monitoring Warfarin therapy and decreasing the intensity of anticoagulation for most indications, the major hemorrhagic risks of Warfarin therapy have decreased substantially over the years, yet Warfarin still tops the list of “Top 10 Drug Interactions.”

Dabigatran (Pradaxa) was FDA-approved in October 2010 and the first oral direct thrombin inhibitor.  It too, is indicated for reduction of risk of stroke and systemic embolism inpatients with non-valvular atrial fibrillation, for treatment and reduction in the risk of (DVT), (PE), and for the prophylaxis of (DVT) and (PE) following hip replacement surgery.  It does not require bloodwork monitoring.

Pradaxa was followed by the Factor Xa Inhibitors … Xarelto in 2011, Eliquis in 2012, Savaysa in 2015.  They all have similar indications and do not require blood work as well.

Do You Know the …..

  • the difference between them all?
  • how to compare?
  • specifics on administration and use?
  • Safety factors of anticoagulants?

 Please Join Jan Pizzolanti, RPh – President of RX Consults as she discusses these important drugs and the best ways to compare, administer and keep our resident safe from harm.

This webinar will be of interest to Administrators and Nurses

Click here to register. 

  Event Categories:

Webinar